Centrica jumps after Sizewell C nuclear plant investment confirmed

Centrica PLC shares jumped over 4% following government approval for the £38 billion Sizewell C nuclear power station, with the company committing £1.3 billion for a 15% stake. The FTSE 100 energy group anticipates a real return on equity of 10.8% and an internal rate of return exceeding 12.00% from this investment, which is projected to grow to a £3 billion equity share at commercial operations, bolstering the UK's long-term zero-carbon electricity supply.

Analysis

Centrica PLC (LSE:CNA) has secured a significant long-term growth catalyst with the UK government's final approval for the Sizewell C nuclear power station. The company's commitment of £1.3 billion for a 15% stake in the £38 billion project solidifies its strategic pivot towards large-scale, zero-carbon energy infrastructure. The market's positive reception was immediate, evidenced by a 4.2% share price jump to 163.25p. For investors, the key financial metrics are compelling: management projects a real return on equity of 10.8% and an internal rate of return exceeding 12.00% under moderate scenarios. Furthermore, Centrica anticipates its equity share will appreciate to £3 billion by the time the plant becomes commercially operational, indicating substantial value creation potential from the initial investment. This move aligns with the national energy security agenda and positions Centrica as a key player in the UK's energy transition, a narrative strongly supported by CEO Chris O’Shea's description of the investment as 'compelling for our shareholders and the country.'

Key Decisions for Investors

• Investors may view this development as a long-term positive, as the Sizewell C investment provides a clear path to regulated, high-visibility earnings with a projected real ROE of 10.8% and an IRR above 12.00%.
• It is prudent to monitor the project's execution and budget adherence, as the £38 billion total cost and multi-stakeholder funding model introduce long-term construction and potential regulatory risks.
• Given the immediate 4.2% share price appreciation, investors should assess whether the current valuation fully reflects the long-term value of the projected £3 billion equity stake at commercial operation, or if further upside remains as the project de-risks over time.